Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.
Health news
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.
The Food and Drug Administration (FDA) has granted Fast Track designation to AD109 for the treatment of obstructive sleep apnea (OSA). AD109 is an investigational, first-in-class, oral medication that contains atomoxetine, a selective norepinephrine reuptake…
Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis. Nabiximols oromucosal spray is an investigational…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Spero Therapeutics regarding the New Drug Application (NDA) for tebipenem HBr (tebipenem pivoxil hydrobromide) for the treatment of adults with complicated…
Pfizer and BioNTech announced positive findings from a study evaluating 2 Omicron-adapted COVID-19 vaccine candidates. The phase 2/3 trial assessed the safety, tolerability, and immunogenicity of a booster (fourth) dose of an Omicron-adapted monovalent vaccine…
The Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel) for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from…
The Food and Drug Administration (FDA) has ordered JUUL Labs Inc to stop selling and distributing its electronic nicotine delivery system (ENDS) in the US. The banned products include the JUUL device and 4 types…
Vi-Jon, LLC is voluntarily recalling 1 lot of CVS Magnesium Citrate Saline Laxative Oral Solution Lemon Flavor, 10 fl oz (296mL) due to microbial contamination with Gluconacetobacter liquefaciens, a Gram-negative bacterium. The affected product lot…
The Food and Drug Administration (FDA) has granted accelerated approval to Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of individuals 6 years of age and older with unresectable or metastatic solid tumors with BRAF…
The Food and Drug Administration (FDA) has granted Orphan Drug designation to VBI-1901 for the treatment of glioblastoma. Glioblastoma is a rare, aggressive, malignant grade IV brain tumor that develops from the glial cells. VBI-1901…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021